Antengene's ATG-207 shows promise in autoimmune disease preclinical trials

Antengene Corporation Limited has unveiled preclinical findings on ATG-207 at EULAR 2026. The company, listed on the Hong Kong Stock Exchange, presented data on its novel bifunctional fusion protein designed to target autoimmune diseases. Early results suggest the drug could selectively suppress harmful immune responses while promoting regulatory T cells.

ATG-207 is an engineered protein that combines CD3 and TGF-β signalling with a preference for binding TGFβRIII. This design allows it to specifically reduce T cell receptor levels on primary T cells. Tests showed it effectively lowered proinflammatory cytokine release compared to an unbiased control.

In experiments, the drug demonstrated strong therapeutic effects in mouse models of autoimmune conditions. These included experimental autoimmune encephalomyelitis and adoptive T cell transfer colitis. The results indicated improved immune regulation and reduced inflammation. Further analysis revealed that ATG-207 enhanced regulatory T cell activity in both healthy donors and patients with systemic lupus erythematosus. Human whole blood assays also confirmed minimal production of pro-inflammatory cytokines. The findings suggest the drug’s potential to remodel T cell function and restore immune tolerance.

The preclinical data highlight ATG-207’s ability to target pathogenic T cells while supporting regulatory immune responses. If further studies confirm these effects, the drug could offer a new approach for treating autoimmune diseases. Antengene plans to continue developing the therapy based on these promising early results.